Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes Innovent Biologics has commenced a Phase 3 study for IBI128, a novel gout treatment, aiming to provide enhanced care for gout patients in China.

Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes #China #Suzhou #Gout_Treatment #Innovent #IBI128

Crystalys Therapeutics Welcomes Former Horizon CEO Tim Walbert as Independent Director to Drive Gout Treatment Innovations Crystalys Therapeutics has appointed Tim Walbert, former CEO of Horizon Therapeutics, as an Independent Director, enhancing its leadership in gout treatments.

Crystalys Therapeutics Welcomes Former Horizon CEO Tim Walbert as Independent Director to Drive Gout Treatment Innovations #United_States #San_Diego #Gout_Treatment #Crystalys_Therapeutics #Tim_Walbert

Crystalys Therapeutics Marks Significant Milestone in RUBY Study with Patient Dosing in Europe Crystalys Therapeutics successfully initiates patient dosing for the RUBY study in Europe, advancing their gout treatment research with dotinurad.

Crystalys Therapeutics Marks Significant Milestone in RUBY Study with Patient Dosing in Europe #United_States #San_Diego #Gout_Treatment #Crystalys_Therapeutics #dotinurad

Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 Innovent Biologics has successfully dosed the first participant in a Phase 1 clinical trial for IBI3011, targeting gout treatment. This monoclonal antibody aims to revolutionize care for patients suffering from gout flares.

Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 #China #Suzhou #Innovent_Biologics #Gout_Treatment #IBI3011

Shanton Pharma Achieves Key Milestone with FDA for Gout Treatment in the U.S. Shanton Pharma has successfully concluded an End-of-Phase 2 meeting with the FDA for its novel gout treatment, SAP-001, marking a crucial development in their clinical program.

Shanton Pharma Achieves Key Milestone with FDA for Gout Treatment in the U.S. #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma Achieves Critical Milestone with FDA for Gout Treatment Development Shanton Pharma announces the successful completion of an End-of-Phase 2 meeting with the FDA for its gout treatment, SAP-001.

Shanton Pharma Achieves Critical Milestone with FDA for Gout Treatment Development #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Crystalys Therapeutics Initiates Phase 3 Trials for Dotinurad in Gout Treatment Crystalys Therapeutics has begun Phase 3 trials for Dotinurad, a promising gout treatment. The first patient was dosed, marking significant progress.

Crystalys Therapeutics Initiates Phase 3 Trials for Dotinurad in Gout Treatment #USA #San_Diego #Gout_Treatment #Crystalys_Therapeutics #dotinurad

Arthrosi's $153 Million Series E Financing: A Milestone in Gout Treatment Development Arthrosi Therapeutics has successfully closed a $153 million Series E financing to advance pozdeutinurad, a next-gen treatment for gout.

Arthrosi's $153 Million Series E Financing: A Milestone in Gout Treatment Development #United_States #San_Diego #Gout_Treatment #pozdeutinurad #Arthrosi

Crystalys Therapeutics Secures $205M Series A for Gout Treatment Revolution Crystalys Therapeutics launches with $205 million in Series A funding to enhance gout treatment options, focusing on the drug dotinurad.

Crystalys Therapeutics Secures $205M Series A for Gout Treatment Revolution #United_States #San_Diego #Gout_Treatment #Crystalys_Therapeutics #dotinurad

Arthrosi Therapeutics Completes Full Enrollment for Pozdeutinurad Phase 3 Trial in Gout Patients Arthrosi Therapeutics announces full enrollment in the Phase 3 trial for Pozdeutinurad, targeting gout treatment. The study aims to improve patient outcomes significantly.

Arthrosi Therapeutics Completes Full Enrollment for Pozdeutinurad Phase 3 Trial in Gout Patients #USA #San_Diego #Arthrosi_Therapeutics #Gout_Treatment #pozdeutinurad

Shanton Pharma's SAP-001 Gains Fast Track Designation from FDA for Gout Treatment Shanton Pharma announces its investigational drug SAP-001 for gout has received Fast Track designation from the FDA, aiming to speed up treatment availability.

Shanton Pharma's SAP-001 Gains Fast Track Designation from FDA for Gout Treatment #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trials with Pozdeutinurad Arthrosi Therapeutics announces over 50% patient enrollment in the pivotal Phase 3 REDUCE 1 trial for their gout drug Pozdeutinurad, showcasing significant progress in research and potential treatment.

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trials with Pozdeutinurad #United_States #San_Diego #Arthrosi_Therapeutics #Gout_Treatment #pozdeutinurad

Arthrosi Shares Promising Results for Pozdeutinurad at EULAR 2025, Highlighting Long-Term Efficacy Arthrosi Therapeutics reveals significant long-term safety and efficacy data for pozdeutinurad in gout treatment at the EULAR 2025 Congress. Researchers confirm its efficacy and tolerability.

Arthrosi Shares Promising Results for Pozdeutinurad at EULAR 2025, Highlighting Long-Term Efficacy #United_States #San_Diego #Gout_Treatment #pozdeutinurad #Arthrosi

Arthrosi Therapeutics Reveals Significant Findings at EULAR Congress 2025 Arthrosi Therapeutics announces its pivotal presentations regarding pozdeutinurad at EULAR 2025, aiming to transform gout treatments.

Arthrosi Therapeutics Reveals Significant Findings at EULAR Congress 2025 #United_States #San_Diego #Arthrosi_Therapeutics #Gout_Treatment #pozdeutinurad

Shanton Pharma to Unveil Promising Phase 2b Data on SAP-001 for Gout at EULAR 2025 Shanton Pharma will present phase 2b trial results for SAP-001 in refractory gout patients at EULAR 2025, highlighting its effectiveness and potential.

Shanton Pharma to Unveil Promising Phase 2b Data on SAP-001 for Gout at EULAR 2025 #USA #Barcelona #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma to Unveil Key Findings on SAP-001 for Gout at EULAR 2025 Congress Shanton Pharma reveals plan to present key data from its Phase 2b study on SAP-001, a new treatment for refractory gout, at EULAR 2025.

Shanton Pharma to Unveil Key Findings on SAP-001 for Gout at EULAR 2025 Congress #USA #Barcelona #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma Reports Encouraging Results in Their Phase 2b Gout Study, Paving the Way for Innovative Treatment Shanton Pharma has released promising data from their Phase 2b study of SAP-001, targeting refractory gout patients. This novel treatment shows breakthrough efficacy.

Shanton Pharma Reports Encouraging Results in Their Phase 2b Gout Study, Paving the Way for Innovative Treatment #USA #Princeton #Gout_Treatment #Shanton #SAP-001

Arthrosi Therapeutics Kicks Off Phase 3 REDUCE 1 Trial for Gout Treatment with First Patient Dosed Arthrosi Therapeutics has commenced its pivotal Phase 3 REDUCE 1 trial of AR882 for gout treatment, marking a significant milestone in gout therapy advancements.

Arthrosi Therapeutics Kicks Off Phase 3 REDUCE 1 Trial for Gout Treatment with First Patient Dosed #United_States #San_Diego #Arthrosi_Therapeutics #AR882 #Gout_Treatment

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trial with AR882 Arthrosi Therapeutics has successfully enrolled over 50% of patients in its Phase 3 REDUCE 2 trial for AR882, a promising treatment for gout. The study aims to redefine patient care and improve the quality of life.

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trial with AR882 #United_States #San_Diego #Arthrosi_Therapeutics #AR882 #Gout_Treatment